Paratek Pharmaceuticals, Inc. short interest in 2021
In 2021, Paratek Pharmaceuticals, Inc.'s disclosed short interest ran from 8.92% of shares outstanding on 15 Jan 2021 to 7.49% on 31 Dec 2021, a change of -1.43 percentage points. The year's high was 9.80% on 26 Feb 2021 and its low 6.56% on 15 Dec 2021, averaging 8.64% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.56 days on 14 May 2021. Full history: Paratek Pharmaceuticals, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023
2021 in figures
- Start of year
- 8.92% (15 Jan 2021)
- End of year
- 7.49% (31 Dec 2021)
- Change
- -1.43 pp
- High
- 9.80% (26 Feb 2021)
- Low
- 6.56% (15 Dec 2021)
- Average
- 8.64%
- Highest days to cover
- 18.56 (14 May 2021)
- SEC filings marked
- 4
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 8.92% | 12.63 | |
| 29 Jan 2021 | 8.82% | 13.50 | |
| 12 Feb 2021 | 9.64% | 7.44 | |
| 26 Feb 2021 | 9.80% | 10.50 | |
| 15 Mar 2021 | 9.75% | 11.76 | |
| 31 Mar 2021 | 9.33% | 16.15 | 10-K filed |
| 15 Apr 2021 | 9.00% | 4.97 | |
| 30 Apr 2021 | 9.35% | 16.22 | |
| 14 May 2021 | 9.08% | 18.56 | |
| 28 May 2021 | 9.01% | 15.65 | 10-Q filed |
| 15 Jun 2021 | 9.36% | 5.06 | |
| 30 Jun 2021 | 8.81% | 3.85 | |
| 15 Jul 2021 | 8.72% | 9.05 | |
| 30 Jul 2021 | 8.98% | 13.22 | |
| 13 Aug 2021 | 9.07% | 7.95 | 10-Q filed |
| 31 Aug 2021 | 9.45% | 8.39 | |
| 15 Sep 2021 | 9.22% | 13.38 | |
| 30 Sep 2021 | 8.26% | 9.28 | |
| 15 Oct 2021 | 7.64% | 15.88 | |
| 29 Oct 2021 | 7.14% | 12.78 | |
| 15 Nov 2021 | 7.13% | 12.94 | 10-Q filed |
| 30 Nov 2021 | 6.84% | 12.05 | |
| 15 Dec 2021 | 6.56% | 12.87 | |
| 31 Dec 2021 | 7.49% | 11.69 |
See also: Paratek Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.